New York, May 22, 2026, 10:05 EDT
• BBOT was near $8.90 in early Nasdaq trading, down from Thursday’s close, and volume was thin.
• U.S. equities were open on Friday; markets are shut Monday for Memorial Day.
• Investors are waiting for new clinical data, expected in the second half of 2026.
BridgeBio Oncology Therapeutics shares slipped early Friday, pausing after a recent bounce as traders waited for later-stage cancer drug results set for this year. BBOT last traded near $8.90, in a session range of $8.85 to $9.25. The Nasdaq Composite was up roughly 0.4%.
Timing is in play here. U.S. stocks traded normal Friday hours before the Memorial Day break on Monday, May 25. This can make small-cap biotech volumes lighter ahead of a long weekend.
BBOT hadn’t posted anything new to its investor site by early Friday morning. The most recent update was still the May 12 Q1 report. So the move in the shares looks driven by positioning or liquidity, not any fresh trial data or filing.
BBOT is a clinical-stage biotech, still relying mostly on human trial data for its valuation since it doesn’t have product sales yet. The company posted a $42.1 million net loss for the first quarter and ended March with $388.9 million in cash, cash equivalents and marketable securities. Management puts the company’s “cash runway” into 2028. BridgeBio Oncology Therapeutics
BBOT CEO Pedro J. Beltran said the quarter had “meaningful progress across all three clinical programs,” talking about the company’s RAS-pathway pipeline. The company is working on blocking RAS and PI3Kα, both known cancer-signaling pathways, to try to slow growth in cancers tied to those mutations. BridgeBio Oncology Therapeutics
BBO-11818 is BridgeBio Oncology Therapeutics’ main focus right now. The drug, a pan-KRAS inhibitor, is in Phase 1 trials, with the main goal to test safety and dosing and check for any early signs of efficacy. Updated Phase 1 data are expected in the second half of 2026, BBOT said.
BBOT chief medical and development officer Yong Ben said FDA Fast Track status for BBO-11818 shows the “importance and urgency of accelerating the development” of the therapy for KRAS-mutant pancreatic cancer. Fast Track can bring faster contact and review from the FDA if there’s no good treatment, but it doesn’t grant approval. BridgeBio Oncology Therapeutics
H.C. Wainwright kept its Buy rating and $29 target on BBOT in late April, pointing to AACR preclinical results for BBO-11818 and BBO-10203. BBOT’s analyst-coverage page names H.C. Wainwright’s Robert Burns as an analyst tracking the stock. Wall Street coverage is still active.
Competition isn’t easy to assess here. Revolution Medicines, which is the bigger player in RAS drugs, has raised expectations in pancreatic cancer after posting late-stage data on daraxonrasib. Relay Therapeutics is also keeping investors focused on PI3K-pathway work with new clinical results this week.
The risks are clear. Early tumor gains may not last in bigger studies, safety could change as patient numbers go up, and BBOT keeps burning through cash. Another SEC filing pointed out that actual or expected sales by securityholders could hit the stock hard.
Right now, trade is thin. This small-cap oncology name sits near its 12-month lows. There’s been little new in the past day. Most action relies on a data calendar for the second half. That could push shares either way before the next update.
